tiprankstipranks
Trending News
More News >
Getinge AB (UK) (SE:GETI.B)
:GETI.B
Advertisement

Getinge (GETI.B) AI Stock Analysis

Compare
0 Followers

Top Page

SE:GETI.B

Getinge

(LSE:GETI.B)

Rating:68Neutral
Price Target:
kr212.00
▲(8.80% Upside)
Getinge's overall stock score is driven primarily by its stable financial performance and positive technical indicators. The company's consistent profitability and improving cash flow are strengths, but the decline in revenue growth and high P/E ratio are concerns. The technical analysis suggests a positive trend, while the valuation indicates potential overvaluation.

Getinge (GETI.B) vs. iShares MSCI Sweden ETF (EWD)

Getinge Business Overview & Revenue Model

Company DescriptionGetinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
How the Company Makes MoneyGetinge makes money primarily through the sale of medical equipment and consumables, as well as providing related services. The company's revenue streams are diversified across its three main sectors. In Acute Care Therapies, Getinge generates revenue by selling products like ventilators, heart-lung machines, and associated consumables. The Life Science sector contributes to revenue through the provision of equipment and services for sterile transfer and contamination prevention. In the Surgical Workflows division, Getinge earns money by offering a range of products and services that improve efficiency in the operating room, including sterilization equipment and operating tables. Additionally, Getinge has established partnerships with hospitals and healthcare facilities, which are significant contributors to its earnings. The company also focuses on service contracts and after-sales services, which provide a steady income stream and strengthen customer relationships.

Getinge Financial Statement Overview

Summary
Getinge's financial performance is solid, with consistent revenue growth and stable profitability. The company maintains a balanced financial structure, though increased leverage and reduced returns on equity could pose risks. Cash flow generation is strong despite a decline in free cash flow.
Income Statement
72
Positive
Getinge demonstrates solid profitability with a strong gross profit margin of approximately 46% and a respectable net profit margin of around 4.2% for TTM. However, both EBIT and EBITDA margins have slightly contracted compared to previous years. Revenue growth is healthy, with a year-over-year increase of 2.3% in the TTM. The company exhibits moderate revenue growth and stable profitability, though declining EBIT margins may require attention.
Balance Sheet
65
Positive
The balance sheet reveals a stable financial structure with an equity ratio of about 50.7%, indicating a balanced asset financing strategy. However, the debt-to-equity ratio has increased to 0.38, reflecting higher leverage compared to prior years. Return on equity stands at 4.8% for the TTM, showing a reduction from previous periods, which suggests potential challenges in generating returns on equity.
Cash Flow
68
Positive
Cash flow analysis indicates a decline in free cash flow growth, with a negative growth rate of approximately -24% compared to the previous annual report. The operating cash flow to net income ratio is robust at 2.57, highlighting efficient cash generation relative to net income. Despite the decline in free cash flow, the company maintains a healthy cash conversion efficiency.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue35.50B34.76B31.83B28.29B27.05B29.82B
Gross Profit16.64B16.15B14.49B13.41B13.58B14.72B
EBITDA6.37B5.31B5.93B5.73B6.20B6.46B
Net Income1.49B1.64B2.41B2.49B2.97B3.24B
Balance Sheet
Total Assets56.37B63.92B53.59B52.03B44.55B45.01B
Cash, Cash Equivalents and Short-Term Investments1.95B2.96B2.73B5.68B4.08B6.06B
Total Debt11.17B10.73B8.08B5.82B4.31B10.21B
Total Liabilities27.35B30.71B23.18B21.58B19.38B23.53B
Stockholders Equity28.82B33.01B30.17B30.04B24.75B21.02B
Cash Flow
Free Cash Flow2.70B3.27B1.60B2.23B5.63B6.15B
Operating Cash Flow4.03B4.58B2.96B3.37B6.56B7.20B
Investing Cash Flow-5.85B-4.55B-6.54B-1.47B-1.33B-1.99B
Financing Cash Flow1.50B504.00M511.00M-500.00M-7.24B-297.00M

Getinge Technical Analysis

Technical Analysis Sentiment
Positive
Last Price194.85
Price Trends
50DMA
189.88
Positive
100DMA
192.91
Positive
200DMA
190.49
Positive
Market Momentum
MACD
0.77
Positive
RSI
53.44
Neutral
STOCH
25.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GETI.B, the sentiment is Positive. The current price of 194.85 is above the 20-day moving average (MA) of 192.82, above the 50-day MA of 189.88, and above the 200-day MA of 190.49, indicating a bullish trend. The MACD of 0.77 indicates Positive momentum. The RSI at 53.44 is Neutral, neither overbought nor oversold. The STOCH value of 25.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GETI.B.

Getinge Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
68
Neutral
kr52.15B35.004.94%2.43%6.51%-42.34%
66
Neutral
kr68.53B121.2732.07%0.31%15.54%39.12%
65
Neutral
kr4.13B27.2918.65%1.50%3.45%4.22%
64
Neutral
$6.20B55.065.17%17.78%-7.83%
54
Neutral
kr18.31B40.243.46%0.78%0.14%
54
Neutral
kr1.51B-5.40%16.27%-22.61%
51
Neutral
$7.39B0.36-62.86%2.37%15.48%-2.68%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:GETI.B
Getinge
194.85
1.57
0.81%
SE:VITR
Vitrolife AB
136.50
-81.89
-37.50%
SE:CEVI
CellaVision AB
167.00
-77.88
-31.80%
SE:XVIVO
Xvivo Perfusion AB
190.90
-326.10
-63.08%
SE:SECT.B
Sectra AB Class B
354.60
119.32
50.71%
SE:SEDANA
Sedana Medical AB
15.44
-7.91
-33.88%

Getinge Corporate Events

Getinge’s Cardiosave Intra-Aortic Balloon Pump CE Mark Reinstated
Aug 4, 2025

Getinge has announced that the EU CE Mark for its Cardiosave Intra-Aortic Balloon Pump has been reinstated by the EU Notified Body TÜV SÜD after addressing compliance gaps and implementing design improvements. This reinstatement allows Getinge to resume deliveries of the device to markets accepting the CE mark, ensuring healthcare professionals and patients have access to this critical cardiac care device.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK180.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Getinge Announces Q2 2025 Report and Conference Call
Jul 4, 2025

Getinge has announced its Q2 Report 2025 will be released on July 18, 2025, followed by a conference call hosted by the company’s President & CEO and CFO. This event invites fund managers, analysts, and media to participate, potentially impacting stakeholders by providing insights into the company’s financial performance and strategic direction.

The most recent analyst rating on ($SE:GETI.B) stock is a Sell with a SEK190.00 price target. To see the full list of analyst forecasts on Getinge stock, see the SE:GETI.B Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 08, 2025